Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II multicenter study designed to evaluate the safety and efficacy of
combination BDR. BDR will be administered in one 21-day treatment cycle followed by four
35-day treatment cycles to patients with WM.
Phase:
Phase 2
Details
Lead Sponsor:
European Myeloma Network
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Centre Hospitalier de Lens Erasmus Medical Center Hospital Clinic of Barcelona Hotel Dieu Hospital IRCCS Policlinico S. Matteo Klinikum der Universitaet Muenchen, Grosshadern Laikon General District Hospital, Athens Laikο General Hospital, Athens Niguarda Hospital Sahlgren´s University Hospital Skane University Hospital Theagenio Cancer Hospital Universitaire Ziekenhuizen Leuven University Hospital, Toulouse University of Athens University of Roma La Sapienza University of Salamanca University of Turin, Italy University of Wuerzburg